Objectives Pregnancy in SLE is associated with increased maternal and fetal risks but its impact on irreversible organ damage ...
Objective The Systemic Immune-Inflammation Index (SII) is an accessible haematological marker reflecting systemic ...
Background Janus kinase inhibitors (JAKis) are emerging therapies for SLE, but concerns regarding thromboembolic risk persist. Clinical trials in SLE have not consistently demonstrated an increased ...
Fertility is often a concern for women with SLE. In addition to known indirect factors that influence the ability of a woman with SLE to become pregnant, such as cytotoxic agents, other medications, ...
Objective To assess the effectiveness of belimumab (BEL) in improving anaemia, thrombocytopenia, lymphopenia and leucopenia in patients with SLE. Conclusion In this real-world cohort, BEL treatment ...
Background Rituximab is associated with high infection rates, but studies of infections following rituximab in youth with childhood-onset SLE (cSLE) are limited. We conducted a retrospective ...
22 Historical aspects of B-cell depletion in SLE (8 October, 2025) ...
Haematologic involvement in patients with systemic lupus erythematosus (SLE) is very common. The principal cytopenias in lupus result in anaemia, white cell deficits and thrombocytopenia. Anaemia may ...
Fumaric acid esters in cutaneous lupus erythematosus Fumaric acid esters (FAEs), established immunomodulatory agents in the treatment of psoriasis and multiple sclerosis, have been investigated for ...
is a global, peer-reviewed, open access lupus journal from LFA, publishing papers on all aspects of lupus and related diseases.
Our purpose was to compile information on the haematological manifestations of systemic lupus erythematosus (SLE), namely leucopenia, lymphopenia, thrombocytopenia, autoimmune haemolytic anaemia (AIHA ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results